X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 
main protease

Günther, S.; Reinke, P. Y. A.; Fernández-García, Y.; Lieske, J.; Lane, T. J.; Ginn, H. M.; Koua, F. H. M.; Ehrt, C.; Ewert, W.; Oberthuer, D.; Yefanov, O.; Meier, S.; Lorenzen, K.; Krichel, B.; Kopicki, J.-D.; Gelisio, L.; Brehm, W.; Dunkel, I.; Seychell, B.; Gieseler, H.; Norton-Baker, B.; Escudero-Pérez, B.; Domaracky, M.; Saouane, S.; Tolstikova, A.; White, T. A.; Hänle, A.; Groessler, M.; Fleckenstein, H.; Trost, F.; Galchenkova, M.; Gevorkov, Y.; Li, C.; Awel, S.; Peck, A.; Barthelmess, M.; Schlünzen, F.; Paulraj, L. X.; Werner, N.; Andaleeb, H.; Ullah, N.; Falke, S.; Srinivasan, V.; Franca, B. A.; Schwinzer, M.; Brognaro, H.; Rogers, C.; Melo, D.; Zaitsev-Doyle, J. J.; Knoska, J.; Murillo, G. E. P.; Mashhour, A. R.; Guicking, F.; Hennicke, V.; Fischer, P.; Hakanpää, J.; Meyer, J.; Gribbon, P.; Ellinger, B.; Kuzikov, M.; Wolf, M.; Beccari, A. R.; Bourenkov, G.; von Stetten, D.; Pompidor, G.; Bento, I.; Panneerselvam, S.; Karpics, I.; Schneider, T. R.; Alai, M. M. G.; Niebling, S.; Günther, C.; Schmidt, C.; Schubert, R.; Han, H.; Boger, J.; Monteiro, D. C. F.; Zhang, L.; Sun, X.; Pletzer-Zelgert, J.; Wollenhaupt, J.; Feiler, C. G.; Weiss, M. S.; Schulz, E.-C.; Mehrabi, P.; Karničar, K.; Usenik, A.; Loboda, J.; Tidow, H.; Chari, A.; Hilgenfeld, R.; Uetrecht, C.; Cox, R.; Zaliani, A.; Beck, T.; Rarey, M.; Günther, S.; Turk, D.; Hinrichs, W.; Chapman, H. N.; Pearson, A .R.; Betzel, C.; Meents, A.

doi:10.1126/science.abf7945

DetailsÜbersicht

X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease

Günther, S., Reinke, P. Y. A., Fernández-García, Y., Lieske, J., Lane, T. J., Ginn, H. M., et al. (2021). X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science, 372(6542), 642-646. doi:10.1126/science.abf7945.

Item is Freigegeben

einblenden: alle ausblenden: alle

Basisdaten

einblenden: ausblenden:

Datensatz-Permalink: https://hdl.handle.net/21.11116/0000-0008-3F69-D Versions-Permalink: https://hdl.handle.net/21.11116/0000-0008-7E09-2

Genre: Zeitschriftenartikel

Dateien

einblenden: Dateien

ausblenden: Dateien

:

642.full.pdf (Verlagsversion), 2MB

Öffnen Speichern

Datei-Permalink:
https://hdl.handle.net/21.11116/0000-0008-7E0A-1

Name:
642.full.pdf

Beschreibung:
This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

OA-Status:

Sichtbarkeit:
Öffentlich

MIME-Typ / Prüfsumme:
application/pdf / [MD5]

Technische Metadaten:

Öffnen

Copyright Datum:
2021

Copyright Info:
© The Authors,some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works

Lizenz:
https://creativecommons.org/licenses/by/4.0/

:

suppl.zip (Ergänzendes Material), 15MB

Öffnen Speichern

Datei-Permalink:
https://hdl.handle.net/21.11116/0000-0008-7E0B-0

Name:
suppl.zip

Beschreibung:
SUPPLEMENT.pdf(Materials and Methods; Supplementary Text; Figs. S1 to S9; Tables S2, S5, and S6; References), TABLE S1.xlsx (Screened drug repurposing libraries. All tested compounds from the "Fraunhofer IME Repurposing Collection" and the "Safe-in-man" library, including information about tested crystals, obtained high-quality datasets and identified hits.), TABLE S4.xlsx (Summary of X-ray crystallographic data processing and refinement statistics), TABLE S7.xlsx (In silico screening of repurposing library against Mpro. The highest ranked 200 compounds of the virtual screening. The names and HYDE scores of the top ranked molecules are given. The yellow background highlights compounds for which high-quality X-ray data was obtained in the X-ray screening. The green background highlights compounds that were detected in the active site in the X-ray screen. Compounds highlighted in light green show a similar binding mode to the fragment with the PDB ligand ID K0G in complex with pro (PDB ID 5R83). Compounds highlighted in light yellow were reported as being active in other screening studies.), TABLE S3.xlsx (Comprehensive summary sheets of hit compounds. Summary showing electron-density maps, compound interactions with Mpro, detailed compound information, biochemical and cell-based antiviral reduction data.), MDAR REPRODUCIBILITY CHECKLIST.pdf

OA-Status:

Sichtbarkeit:
Öffentlich

MIME-Typ / Prüfsumme:
application/zip / [MD5]

Technische Metadaten:

Öffnen

Copyright Datum:
-

Copyright Info:
-

Lizenz:
-

Externe Referenzen

einblenden:

ausblenden:

externe Referenz:
https://dx.doi.org/10.1126/science.abf7945 (Verlagsversion) Open Access Status unbekannt

Beschreibung:
-

OA-Status:

externe Referenz:
https://dx.doi.org/10.1101/2020.11.12.378422 (Preprint) Open Access Status unbekannt

Beschreibung:
-

OA-Status:

Urheber

einblenden:

ausblenden:

Urheber:
Günther, S.¹, Autor
Reinke, P. Y. A.¹, Autor
Fernández-García, Y.¹, Autor
Lieske, J.¹, Autor
Lane, T. J.¹, Autor
Ginn, H. M.¹, Autor
Koua, F. H. M.¹, Autor
Ehrt, C.¹, Autor
Ewert, W.¹, Autor
Oberthuer, D.¹, Autor
Yefanov, O.¹, Autor
Meier, S.¹, Autor
Lorenzen, K.¹, Autor
Krichel, B.¹, Autor
Kopicki, J.-D.¹, Autor
Gelisio, L.¹, Autor
Brehm, W.¹, Autor
Dunkel, I.¹, Autor
Seychell, B.¹, Autor
Gieseler, H.¹, Autor
Norton-Baker, B.^{2, 3}, AutorEscudero-Pérez, B.¹, AutorDomaracky, M.¹, AutorSaouane, S.¹, AutorTolstikova, A.¹, AutorWhite, T. A.¹, AutorHänle, A.¹, AutorGroessler, M.¹, AutorFleckenstein, H.¹, AutorTrost, F.¹, AutorGalchenkova, M.¹, AutorGevorkov, Y.¹, AutorLi, C.¹, AutorAwel, S.¹, AutorPeck, A.¹, AutorBarthelmess, M.¹, AutorSchlünzen, F.¹, AutorPaulraj, L. X.^{4, 5}, Autor Werner, N.¹, AutorAndaleeb, H.¹, AutorUllah, N.¹, AutorFalke, S.¹, AutorSrinivasan, V.¹, AutorFranca, B. A.¹, AutorSchwinzer, M.¹, AutorBrognaro, H.¹, AutorRogers, C.¹, AutorMelo, D.¹, AutorZaitsev-Doyle, J. J.¹, AutorKnoska, J.¹, AutorMurillo, G. E. P.¹, AutorMashhour, A. R.¹, AutorGuicking, F.¹, AutorHennicke, V.¹, AutorFischer, P.¹, AutorHakanpää, J.¹, AutorMeyer, J.¹, AutorGribbon, P.¹, AutorEllinger, B.¹, AutorKuzikov, M.¹, AutorWolf, M.¹, AutorBeccari, A. R.¹, AutorBourenkov, G.¹, Autorvon Stetten, D.¹, AutorPompidor, G.¹, AutorBento, I.¹, AutorPanneerselvam, S.¹, AutorKarpics, I.¹, AutorSchneider, T. R.¹, AutorAlai, M. M. G.¹, AutorNiebling, S.¹, AutorGünther, C.¹, AutorSchmidt, C.¹, AutorSchubert, R.¹, AutorHan, H.¹, AutorBoger, J.¹, AutorMonteiro, D. C. F.¹, AutorZhang, L.¹, AutorSun, X.¹, AutorPletzer-Zelgert, J.¹, AutorWollenhaupt, J.¹, AutorFeiler, C. G.¹, AutorWeiss, M. S.¹, AutorSchulz, E.-C.², AutorMehrabi, P.², AutorKarničar, K.¹, AutorUsenik, A.¹, AutorLoboda, J.¹, AutorTidow, H.¹, AutorChari, A.¹, AutorHilgenfeld, R.¹, AutorUetrecht, C.¹, AutorCox, R.¹, AutorZaliani, A.¹, AutorBeck, T.¹, AutorRarey, M.¹, AutorGünther, S.¹, AutorTurk, D.¹, AutorHinrichs, W.¹, AutorChapman, H. N.¹, AutorPearson, A .R.¹, AutorBetzel, C.¹, AutorMeents, A.¹, Autor mehr..

Affiliations:
1external, ou_persistent22
2Miller Group, Atomically Resolved Dynamics Department, Max Planck Institute for the Structure and Dynamics of Matter, Max Planck Society, ou_1938288
3Department of Chemistry, UC Irvine, ou_persistent22
4Center for Free-Electron Laser Science, DESY, ou_persistent22
5International Max Planck Research School for Ultrafast Imaging & Structural Dynamics (IMPRS-UFAST), Max Planck Institute for the Structure and Dynamics of Matter, Max Planck Society, ou_2266714

Inhalt

einblenden:

ausblenden:

Schlagwörter: -

Zusammenfassung: The coronavirus disease (COVID-19) caused by SARS-CoV-2 is creating tremendous human suffering. To date, no effective drug is available to directly treat the disease. In a search for a drug against COVID-19, we have performed a high-throughput x-ray crystallographic screen of two repurposing drug libraries against the SARS-CoV-2 main protease (M^pro), which is essential for viral replication. In contrast to commonly applied x-ray fragment screening experiments with molecules of low complexity, our screen tested already-approved drugs and drugs in clinical trials. From the three-dimensional protein structures, we identified 37 compounds that bind to M^pro. In subsequent cell-based viral reduction assays, one peptidomimetic and six nonpeptidic compounds showed antiviral activity at nontoxic concentrations. We identified two allosteric binding sites representing attractive targets for drug development against SARS-CoV-2.

Details

einblenden:

ausblenden:

Sprache(n): eng - English

Datum: Eingereicht: 2020-11-20Angenommen: 2021-03-29Online veröffentlicht: 2021-04-02Erschienen: 2021-05-07

Publikationsstatus: Erschienen

Seiten: 5

Ort, Verlag, Ausgabe: -

Inhaltsverzeichnis: -

Art der Begutachtung: Expertenbegutachtung

Identifikatoren: DOI: 10.1126/science.abf7945

Art des Abschluß: -

Projektname : -

Grant ID : 101003551

Förderprogramm : Horizon 2020 (H2020)

Förderorganisation : European Commission (EC)

Projektname : -

Grant ID : 759661

Förderprogramm : Horizon 2020 (H2020)

Förderorganisation : European Commission (EC)

Quelle 1

einblenden:

ausblenden:

Titel: Science

Kurztitel : Science

Genre der Quelle: Zeitschrift

Urheber:

Affiliations:

Ort, Verlag, Ausgabe: Washington, D.C. : American Association for the Advancement of Science

Seiten: - Band / Heft: 372 (6542) Artikelnummer: - Start- / Endseite: 642 - 646 Identifikator: ISSN: 0036-8075
CoNE: https://pure.mpg.de/cone/journals/resource/991042748276600_1

Datensatz

Basisdaten

Dateien

Externe Referenzen

Urheber

Inhalt

Details

Veranstaltung

Entscheidung

Projektinformation

Quelle 1